李宝力 博士，副研究员，博士生导师，药学院副院长和工会副主席。其所在团队构建了具有独特研究风格的，含1400 种已上市化学药物的实体库和含1370种药用植物的提取物库，通过多学科交叉合作，针对衰老及相关疾病、耐药致病菌感染等临床急需领域，初步建立了“老药二次开发”体系：发现新用途老药先导、确证作用机制或靶标（晶体结构）、开展老药二次优化改造与研发。近5年来，在Journal of Medicinal Chemistry、Acta Pharmaceutica Sinica B、European Jour nal of Medicinal Chemistry等期刊发表SCI论文18篇；已申请发明专利14项（含PCT专利1项），其中已授权国际专利3项和中国专利3项；主持国自然青年基金1项、国自然地区基金1项、海南省自然青年基金1项、海南大学高层次人才启动经费1项、海南大学协同创新经费1项，参与国自然重点项目1项（子课题负责人，分配经费115万）、国自然面上基金1项、美国Bank head-Coley基金1项（450万）；参编《药学英语》教材（副主编）。其所设计合成的候选新药JX08-2，以1.4亿元转让给丽珠医药集团股份公司。

 邮箱： baolili@hainanu.edu.cn

 1. 教育背景

 2018.09 — 2021.09：墨菲特癌症研究中心，药物开发部，博士后研究员；

 2013.09 — 2018.06：华东理工大学，药学院，药学专业，博士（硕博连读）；

 2009.09 — 2013.06：华东理工大学，药学院，药物制剂专业、英语专业，双学士。

2.研究领域

药物化学合成、分子设计、靶标发现及作用机制研究

3.教学情况

药物化学、药学英语

4.社会兼职

中国中医药信息学会中医临床药学分会常务理事

中国灾害防御协会应急救援药物和特医食品分会（筹）副秘书长

《中国药物化学杂志》首届青年编委

5．发表论文 (†第一作者、并列第一作，*通讯作者)

1）Zhifan Mao†, Wenwen Liu†, Rong Zou†, Ling Sun†, Lingyu Wu, Liru Chen, Zhouzhi Song, Shuman Huang, Yunyuan Huang, Yong Rao, Yi-You Huang, Baoli Li*, Zelan Hu*, and Jian Li*. Glibenclamide targets MDH2 to relieve aging phenotypes through metabolism-regulated epigenetic modification. Signal Transduction and Targeted Therapy, 2024 (under review).

2）Taotao Lu†, Hongguang Han†, Chaohui Wu†, Qian Li, Hongyan Hu, Wenwen Liu, Donglei Shi, Feifei Chen, Lefu Lan, Jian Li, Shihao Song, Baoli Li*. Discovery of a novel polymyxin adjuvant against multidrug-resistant Gram-negative bacteria through oxidative stress modulation. Acta Pharmaceutica Sinica B, 2024 (under review).

3）Xiao Lia†, Yue Yao†, Luoyifan Zhou†, Jin Yang, Xin Chen, Chao Zhang, Manjiong Wang, Jian Li*, Baoli Li*, and Yixiang Xu*. Glyceraldehyde derivatives inspired by empagliflozin as potential anti-heart failure agents independent of glucose-lowering effects. Acta Materia Medica, 2024, 3(2), 133-146.

4）Haolan You†, Yihe Song†, Yi Yang†, Xicheng Wang, Shiqi Pan, Junyang Huang, Qiqi Shao, Donglei Shi, Baoli Li*, Jian Li*, Xiaokang Li*. European Journal of Medicinal Chemistry. 2024，278，116800

5）Ru Zeng, Taotao Lu, Lingyu Wu, Qing Zhang, Donglei Shi, Jian Li, Shihao Song*, Baoli Li*. Structural modification and activity evaluation of sensitizers against drug-resistant Pseudomonas aeruginosa DK2. Journal of Shenyang Pharmaceutical University 2023, 40, 1587-1597.

6）Taotao Lu†, Xinyu Zheng†, Fei Mao, Qiao Cao, Qin Cao, Jin Zhu, Lefu Lan*, Baoli Li*, Jian Li*, Novel niclosamide-derived adjuvants elevating the efficacy of polymyxin B against MDR Pseudomonas aeruginosa DK2, European Journal of Medicinal Chemistry. 2022, 236, 114318.

7）Xinming Li, Donglei Shi, Yihe Song, Yixiang Xu, Ying Gao, Wenjing Qiu, Xin Chen, Xiaokang Li, Yunyuan Huang, Yanjun Feng, Baoli Li*, Yuan Guo*, Jian Li*, Specific tracking of monoamine oxidase A in HF models by a far-red fluorescent probe with an ultra large Stokes shift, Chinese Chemical Letters, 2021, 33, 1572-1576.

8）Ryan R Davis, Baoli Li, Sang Y Yun, Alice Chan, Pradeep Nareddy, Steven Gunawan, Muhammad Ayaz, Harshani R. Lawrence, Gary W. Reuther, Nicholas J. Lawrence, Ernst Schönbrunn*, Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof, Journal of Medicinal Chemistry, 2021, 64, 2228-2241.

9）Keting Bao, Yongyun Li, Jinlian Wei, Ruoxi Li, Jie Yang, Jiahao Shi, Baoli Li, Jin Zhu, Fei Mao, Renbing Jia, and Jian Li. Fangchinoline suppresses conjunctival melanoma by directly binding FUBP2 and inhibiting the homologous recombination pathway. Cell Death and Disease. 2021, 12, 380.

10）Xin Chen, Xi Yang, Fei Mao, Jinlian Wei, Yixiang Xu, Baoli Li, Jin Zhu, Shuaishuai*, Lijun Jia*, Jian Li*. Development of novel benzimidazole-derived neddylation inhibitors for suppressing tumor growth in vitro and in vivo. European Journal of Medicinal Chemistry. 2021, 210, 112964.

11）Xiaokang Li†, Jian Lu†, Yixiang Xu†, Jiaying Wang, Xiaoxia Qiu, Lei Fan, Baoli Li, Wenwen Liu, Fei Mao, Jin Zhu, Xu Shen*, Jian Li*, Discovery of nitazoxanide-based derivatives as autophagy activators for the treatment of Alzheimer's disease, Acta Pharmaceutica Sinica B, 2020, 10, 646-666.

12）Shuaishuai Ni†, Xin Chen†, Qing Yu†, Yixiang Xu, Zhiguo Hu, Junqian Zhang, Wenjuan Zhang, Baoli Li, Xi Yang, Fei Mao, Jing Huang, Yi Sun, Jian Li*, Lijun Jia*, Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth, European Journal of Medicinal Chemistry, 2020, 185, 111848.

13）Shuaishuai Ni†, Baoli Li†, Yixiang Xu†, Fei Mao, Xiaokang Li, Lefu Lan, Jin Zhu, Jian Li*, Targeting virulence factors as an antimicrobial approach: Pigment inhibitors, Medicinal Research Reviews, 2020, 40, 293-338.

14）Hanwen Wei†, Fei Mao†, Shuaishuai Ni†, Feifei Chen, Baoli Li, Xiaoxia Qiu, Linghao, Hu, Manjiong Wang, Xinyu Zheng, Jin Zhu, Lefu Lan*, Jian Li*. Discovery of novel piperonyl derivatives as diapophytoene desaturase inhibitors for the treatment of methicillin-, vancomycin- and linezolid-resistant Staphylococcus aureus infections, European Journal of Medicinal Chemistry, 2018, 145, 235-251.

15）Shuaishuai Ni†, Baoli Li†, Feifei Chen†, Hanwen Wei, Fei Mao, Yifu Liu, Yixiang Xu, Xiaoxi Qiu, Xiaokang Li, Wenwen Liu, Linghao Hu, Dazheng Ling, Manjiong Wang, Xinyu Zheng, Jin Zhu*, Lefu Lan*, Jian Li*, Novel staphyloxanthin inhibitors with improved potency against multidrug resistant staphylococcus aureus, ACS Medicinal Chemistry Letter, 2018, 9, 233-237.

16）Baoli Li†, Shuaishuai Ni†, Fei Mao†, Feifei Chen, Yifu Liu, Hanwen Wei, Wenhua Chen, Jin Zhu, Lefu Lan*, Jian Li*, Novel terminal bipheny-based diapophytoene desaturases (CrtN) inhibitors as anti-MRSA/VISR/LRSA agents with reduced hERG activity, Journal of Medicinal Chemistry, 2018, 61, 224-250.

17）Baoli Li†, Shuaishuai Ni†, Feifei Chen, Fei Mao, Hanwen Wei, Yifu Liu, Jin Zhu, Lefu Lan*, Jian Li*, Discovery of potent benzocycloalkane derived diapophytoene desaturase (CrtN) inhibitors with enhanced safety profile for the treatment of MRSA, VISA and LRSA infection, ACS Infectious Disease, 2018, 4, 208-217.

18）Baoli Li†, Xinyu Zheng, Manjiong Wang, Keting Bao, Fei Mao*. Synthesis and antitumor activity of δ-lactam compounds. Chinese Journal of Medicinal Chemistry, 2018, 03, 173-183.

19）Shuaishuai Ni†, Hanwen Wei†, Baoli Li†, Feifei Chen, Yifu Liu, Wenhua Chen, Yixiang Xu, Xiaoxia Qiu, Xiaokang Li, Yanli Lu, Wenwen Liu, Linhao Hu, Dazheng Lin, Manjiong Wang, Xinyu Zheng, Fei Mao, Jin Zhu, Lefu Lan*, Jian Li*, Novel inhibitors of staphyloxanthin virulence factor in comparison with linezolid and vancomycin versus methicillin-resistant, linezolid-resistant, and vancomycin-intermediate staphylococcus aureus infections in vivo, Journal of Medicinal Chemistry, 2017, 60, 8145-8159.

20）Sheng Ma†, Jing Deng†, Baoli Li†, Xiujiang Li, Zhaowei Yan, Jin Zhu, Gang Chen, Zhong Wang*, Hualiang Jiang, Liyan Miao*, Jian Li*. Development of second-generation small-molecule RhoA inhibitors with enhanced water solubility, tissue potency, and significant in vivo efficacy, ChemMedChem, 2015, 10, 193-206.

21）Baoli Li†, Fang Xiao*, Wenchao Lu, Yuyun Sun, Jin Zhu, Jian Li*, Discovery and synthesis of N2, N4-substitued-cycloalkyl [d] pyrimidine-2, 4-diamine analogs: The first examples of small-molecular FGFR-1, Chinese Chemical Letters, 2014, 25, 989-994.

6．已授权发明专利

1） 李剑、蓝乐夫、倪帅帅、陈菲菲、魏汉文、刘毅夫、李宝力、毛斐、朱进；苯并含氧脂肪环甲胺类化合物，2021年1月13日，中国，ZL201611073277.2.

2） Li, Jian; Lan, Lefu; Li, Baoli; Chen, Feifei; Ni, Shuaishuai; Liu, Yifu; Wei, Hanwen; Mao, Fei; Zhu, Jin. BENZOHETEROCYCLYL ALKYLAMINE COMPOUNDS AND USE THEREOF. 2020年11月10日, US, 10829464.

3） 李剑；蓝乐夫；李宝力；陈菲菲；倪帅帅；刘毅夫；魏汉文；毛斐；朱进；苯并杂环环烷基胺类化合物及其用途，2020年8月18日, 中国，ZL201611037724.9.

7．荣誉奖励

教育部自然科学一等奖（2022）

上海市优秀共青团员（2015）

第八届“挑战杯”中国大学生创业计划竞赛铜奖（2012）

 欢迎具有药学、化学、生物学背景的同学报考本课题组研究生。